CD38 and plasma cell myeloma: Subsequent studies identified the pan-histone deacetylase (HDAC) inhibitor panobinostat,13 the thalidomide analog lenalidomide,14 the JAK inhibitor ruxolitinib,15 and the DNA methyltransferase (DNMT) inhibitor azacytidine (Aza)16 as agents that could lead to myeloma surface CD38 increase.